Larimar Therapeutics, Inc.

NasdaqGM LRMR

Larimar Therapeutics, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2024: -32.37%

Larimar Therapeutics, Inc. Return on Assets (ROA) is -32.37% for the Trailing 12 Months (TTM) ending September 30, 2024, a -19.37% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Larimar Therapeutics, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2023 was -27.12%, a 32.84% change year over year.
Larimar Therapeutics, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2022 was -40.38%, a 33.56% change year over year.
Larimar Therapeutics, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2021 was -60.78%, a -11.30% change year over year.
Larimar Therapeutics, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2020 was -54.62%.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NasdaqGM: LRMR

Larimar Therapeutics, Inc.

CEO	Dr. Carole S. Ben-Maimon M.D.
IPO Date	June 19, 2014
Location	United States
Headquarters	Three Bala Plaza East
Employees	42
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Key trends

Past 5 years